UCB Receives U.S. FDA Breakthrough Therapy Designation for Cimzia (certolizumab pegol) in Pregnant Women with Antiphospholipid Syndrome (APS)
RegulatoryCimziaPositive
AI Analysis
Summary
UCB announced that the FDA has granted Breakthrough Therapy Designation to Cimzia (certolizumab pegol) for treating pregnant women with antiphospholipid syndrome, accelerating the drug's development pathway.
Outcome Details
Breakthrough Therapy Designation granted by FDA
Importance:8/10
Sentiment:
0.80
FDABreakthrough Therapy DesignationCimziaAntiphospholipid SyndromePregnancy
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 9, 2026 10:09 PM